InfuSystem Reports Q1 2026 Financial Results with $33.7M Revenue and Increased Net Income

InfuSystem Holdings, Inc. reported its financial results for the first quarter of 2026, revealing a net revenue of $33.7 million, a decrease of 3.0% from $34.7 million in the same period last year. The decline was primarily driven by a significant drop in the Device Solutions segment, which saw revenues fall by 16.9% to $11.6 million, while the Patient Services segment experienced a 6.4% increase, reaching $22.1 million. The overall gross profit for the quarter was $19.7 million, reflecting a 2.7% increase from $19.2 million in the prior year, attributed to improved gross margins despite lower net revenues.

The company’s operating income for the quarter was $1.6 million, a notable increase from $0.6 million in the previous year. This improvement was supported by a reduction in selling, general, and administrative expenses, which totaled $18.1 million, down from $18.5 million in the same quarter of 2025. InfuSystem reported a net income of $1.0 million, or $0.05 per share, compared to a net loss of $0.3 million, or $(0.01) per share, in the prior year. The increase in profitability was attributed to higher gross profit margins and lower operational costs.

In terms of operational developments, InfuSystem's Patient Services segment benefited from increased treatment volumes in oncology and wound care, which contributed to a $1.1 million increase in wound care revenues. The company also noted a decrease in pain management revenues, which fell by 15.1%. The Device Solutions segment faced challenges, particularly in biomedical services, which saw a revenue decline of $1.3 million due to a restructuring of a contract with GE Healthcare. The company continues to focus on expanding its service offerings and enhancing its operational efficiencies.

As of March 31, 2026, InfuSystem's total assets were reported at $98.7 million, a slight decrease from $100.6 million at the end of 2025. The company’s cash and cash equivalents stood at $2.1 million, down from $3.2 million. Total liabilities decreased to $39.9 million from $43.2 million, primarily due to a reduction in current liabilities. The company’s stockholders’ equity increased to $58.7 million, reflecting a positive shift in retained earnings following the net income reported for the quarter.

Looking ahead, InfuSystem remains optimistic about its growth prospects, particularly in the Patient Services segment, where it aims to leverage its expertise in outpatient care and expand its service offerings. The company is also focused on integrating its recent acquisition of Apollo Medical Supply, which is expected to enhance its wound care capabilities. Despite the challenges faced in the Device Solutions segment, InfuSystem is committed to improving operational efficiencies and maintaining compliance with its credit agreements, ensuring adequate liquidity for future growth initiatives.